Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Cloudbreak Pharma / Equity Capital Markets

<ul>
<li>Cloudbreak Pharma, a China-based clinical-stage biotechnology company, plans to raise up to US$200m via a Hong Kong listing.</li>
<li>In this note, we examine the company's core products, namely CBT-001 and CBT-009, for pterygium and juvenile myopia respectively.</li>
<li>We are seeing a lack of convincing sustainable innovation from the company. Pre-IPO investors and management are mediocre.</li>
</ul>


Cloudbreak Pharma, a China-based clinical-stage biotechnology company, plans to raise up to US$200m via a Hong Kong listing.
In this note, we examine the company's core products, namely CBT-001 and CBT-009, for pterygium and juvenile myopia respectively.
We are seeing a lack of convincing sustainable innovation from the company. Pre-IPO investors and management are mediocre.


Cloudbreak Pharma (拨康视云) Pre-IPO: Old Drug, New Formulation